Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand
Executive Summary
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
You may also be interested in...
Bayer Spreads Aleve Brand Into Topical Pain Relief
Three-product AleveX line contains menthol and camphor for minor muscle and joints aches and pains with a cooling sensation. Bayer Healthcare promotes launch with an ad campaign featuring basketball legend and TV personality Charles Barkley.
North Carolina Facility Doubles MedPharm Footprint For Developing Topicals, Transdermals
UK firm opens site in North Carolina’s Research Triangle Park to expand its contract formulation development services for OTC and Rx topical and transdermal products. It has supported projects with six of the eight leading OTC companies.
OTC Decisions August-October: More Providers Enter Diclofenac, Lansoprazole, Loratadine Markets
CDER’s August-September OTC application approvals are highlighted by Arbor Pharmaceuticals’ ivermectin 0.5% lice treatment. Orange Book changes also include four firms’ approvals for labeling to market generic equivalents of Voltaren Arthritis Relief launched as an OTC switch since earlier in 2020.